The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Kissei's Japan sales performance.
More than 60 countries have already approved this Polivy combination for the treatment of adult patients with previously untreated DLBCL, including in the EU, UK, Japan, Canada and China.
EU, Japan and other countries.
The company also said at the start of the year that it will be acquiring Japan-based DNA supplier OriCiro Genomics K.K for $85m, marking its first acquisition since its
Opdivo is currently approved in more than 65 countries, including the US, EU, Japan and China for a range of indications such as melanoma, lung, kidney and gastric cancers.
We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to...